1. Market Research
  2. > BTG plc – Product Pipeline Review – 2013

BTG plc – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 81 pages

BTG plc – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “BTG plc - Product Pipeline Review - 2013” provides data on the BTG plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BTG plc’s corporate website, SEC filings, investor presentations and featured press releases, both from BTG plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BTG plc - Brief BTG plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BTG plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BTG plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BTG plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BTG plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BTG plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BTG plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BTG plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BTG plc and identify potential opportunities in those areas.

Table Of Contents

BTG plc - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
BTG plc Snapshot 6
BTG plc Overview 6
Key Information 6
Key Facts 6
BTG plc - Research and Development Overview 7
Key Therapeutic Areas 7
BTG plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
BTG plc - Pipeline Products Glance 11
BTG plc - Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
BTG plc - Drug Profiles 12
glucarpidase 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
polidocanol 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
BTG plc - Pipeline Products by Route of Administration 15
BTG plc - Recent Pipeline Updates 16
BTG plc - Dormant Projects 20
BTG plc - Discontinued Pipeline Products 21
Discontinued Pipeline Product Profiles 21
(caricotamide + tretazicar) 21
AZD-9773 21
BGC-20-0166 21
BGC-20-0582 22
BGC-20-1259 22
BGC-200134 22
BTG-6001 22
BTG-6228 22
CM-3 23
BTG plc - Company Statement 24
BTG plc - Locations And Subsidiaries 25
Head Office 25
Other Locations and Subsidiaries 25
BTG plc, Recent Developments 26
BTG plc- Press Release 26
Apr 22, 2013: SCM Pharma Supports Clinical Scale-up Of BTG's Varisolve 26
Apr 12, 2013: BTG Announces FDA Acceptance Of NDA For Varisolve 26
Feb 04, 2013: BTG Submits NDA For Varisolve To FDA 26
Oct 25, 2010: AstraZeneca Initiates Phase IIB Study For AZD9773 As Treatment For Severe Sepsis 26
Sep 16, 2010: BTG Initiates First Varisolve US Phase III Trial For Treatment Of Varicose Veins 27
Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of CroFab 28
Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of DigiFab 28
Aug 13, 2010: Liver Metastases Clinical Trail Referenced By Cancer research UK 29
Feb 04, 2010: BTG Receives First European Regulatory Approval For DigiFab 29
Jan 21, 2010: BTG Plc Commences Phase IIa Study Of Pleneva For Multiple Sclerosis 30
Financial Deals Landscape 31
BTG plc, Deals Summary 31
BTG plc, Pharmaceuticals and Healthcare, Deal Details 33
Asset Transactions 33
BTG To Acquire Targeted Therapies Business Of Nordion For US$200 Million 33
Biocompatibles International Acquires Bead Technology Patents From BioCure 35
Biocompatibles International Completes Acquisition Of Cancer Diagnostic Products And Intellectual Property From Astron Clinica 37
BTG International Acquires Novel Opioid Agonist From CLL Pharma 39
Venture Financing 41
Xention Secures US$13 Million In Series D Venture Financing 41
Xention Discovery Secures US$3.4 Million In Series B Financing Round 43
Partnerships 45
Philips Partners Biocompatibles To Advance Image Guided Transarterial Embolizations In Interventional Oncology 45
MedX Health Enters Into An Agreement With Biocompatibles International 47
BTG Enters Into Co-Marketing Agreement With Nycomed 48
IsoRay Enters Into Distribution Agreement With Biocompatibles International 50
Biocompatibles Enters Into Co-Development Agreement With AstraZeneca 51
PolyTherics Expands Co-Development Agreement With Biocompatibles 52
Licensing Agreements 53
BTG Enters Into Licensing Agreement With Ohara Pharma For Glucarpidase 53
Ariel Pharma Enters Into Licensing Agreement With BTG International For AP-1531 54
BTG Enters Into Licensing Agreement With Wellstat Therapeutics For Uridine Triacetate 55
BTG Enters Into Licensing Agreement With Allergan 56
Eisai Enters Into Licensing Agreement With Biocompatibles International 57
BTG International Enters Into Licensing Agreement With Onyx Pharma 58
BTG Enters Into License Agreement With Novacea For AQ4N 59
Equity Offering 60
BTG Completes Private Placement Of Shares For US$160 Million 60
Asset Transactions 62
MedX Health Acquires Siascopy Assets From BTG For US$0.3 Million 62
BTG International Sells HySolv Drug Delivery Technology To Novartis Pharma 64
Acquisition 66
BTG To Acquire Ekos, Developer Of Drug Delivery System, For US$220 Million 66
BTG International Acquires Biocompatibles 70
BTG International Acquires Protherics 73
Biocompatibles International Completes Acquisition Of BrachySciences For US$21.4 Million 75
Novartis Acquires Protez Pharma From BTG International 77
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables

BTG plc, Key Information 6
BTG plc, Key Facts 6
BTG plc - Pipeline by Indication, 2013 8
BTG plc - Pipeline by Stage of Development, 2013 9
BTG plc - Monotherapy Products in Pipeline, 2013 10
BTG plc - Filed, 2013 11
BTG plc - Pipeline By Route of Administration, 2013 15
BTG plc - Recent Pipeline Updates, 2013 16
BTG plc - Dormant Developmental Projects,2013 20
BTG plc - Discontinued Pipeline Products, 2013 21
BTG plc, Subsidiaries 25
BTG plc, Deals Summary 31
BTG To Acquire Targeted Therapies Business Of Nordion For US$200 Million 33
Biocompatibles International Acquires Bead Technology Patents From BioCure 35
Biocompatibles International Completes Acquisition Of Cancer Diagnostic Products And Intellectual Property From Astron Clinica 37
BTG International Acquires Novel Opioid Agonist From CLL Pharma 39
Xention Secures US$13 Million In Series D Venture Financing 41
Xention Discovery Secures US$3.4 Million In Series B Financing Round 43
Philips Partners Biocompatibles To Advance Image Guided Transarterial Embolizations In Interventional Oncology 45
MedX Health Enters Into An Agreement With Biocompatibles International 47
BTG Enters Into Co-Marketing Agreement With Nycomed 48
IsoRay Enters Into Distribution Agreement With Biocompatibles International 50
Biocompatibles Enters Into Co-Development Agreement With AstraZeneca 51
PolyTherics Expands Co-Development Agreement With Biocompatibles 52
BTG Enters Into Licensing Agreement With Ohara Pharma For Glucarpidase 53
Ariel Pharma Enters Into Licensing Agreement With BTG International For AP-1531 54
BTG Enters Into Licensing Agreement With Wellstat Therapeutics For Uridine Triacetate 55
BTG Enters Into Licensing Agreement With Allergan 56
Eisai Enters Into Licensing Agreement With Biocompatibles International 57
BTG International Enters Into Licensing Agreement With Onyx Pharma 58
BTG Enters Into License Agreement With Novacea For AQ4N 59
BTG Completes Private Placement Of Shares For US$160 Million 60
MedX Health Acquires Siascopy Assets From BTG For US$0.3 Million 62
BTG International Sells HySolv Drug Delivery Technology To Novartis Pharma 64
BTG To Acquire Ekos, Developer Of Drug Delivery System, For US$220 Million 66
BTG International Acquires Biocompatibles 70
BTG International Acquires Protherics 73
Biocompatibles International Completes Acquisition Of BrachySciences For US$21.4 Million 75
Novartis Acquires Protez Pharma From BTG International 77

List of Figures

BTG plc - Pipeline by Indication, 2013 8
BTG plc - Pipeline by Stage of Development, 2013 9
BTG plc - Monotherapy Products in Pipeline, 2013 10

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.